Mobile website
Basic Research
Inhibitory effect of recombinant human endostatin combined with rAd/P53 on transplanted human breast cancer in nude mice
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Abstract Objective: To investigate the inhibitory effect of recombinant human endostatin （ES）combined with rAd P53 on transplanted human breast cancer cell MCF7 in nude mice. Methods: Animal breast cancer model was established by inoculating MCF7 cells in nude mice. The animals were randomized into control group, ES group, rAd/P53 group, and ES+ rAd/P53 group. The tumor growth was observed in each group and immunohistochemical method was employed to examine the microvessel density (MVD) and the expression of vascular endothelial growth factor (VEGF). Results: Tumor growth was significantly inhibited in all the 3 treatment groups (P<0.05), with the inhibitory rates being 51.67％，48.74％ and 75.54％ in ES, rAd/P53, and ES + rAd/P53 group, respectively. The value of MVD in control, ES , rAd/P53, and ES + rAd/P53 group were 31.17±2.48, 20.33±4.84, 22.33±3.88 and 12.50±2.74，respectively; and their VEGF Hscores were 45.33±5.89, 33.67±4.80, 40.17±4.74 and 22.33±4.41, respectively. The MVD value and VEGF expression in the ES+rAd/P53 group were significantly lower than those of the other groups (P<0.01).Conclusion:Recombinant human endostatin combined with rAd/P53 can greatly inhibit the growth of transplanted human breast tumor in nude mice and reduce the formation of capillary.
Keywords:
Project Supported:
Surpported by the Capital Medical Development Foundation of Beijing (No.20051161)
Clc Number:
